Stocks and Investing
Stocks and Investing
Wed, November 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andreas Argyrides Reiterated (ASND) at Buy and Held Target at $192 on, Nov 8th, 2023
Andreas Argyrides of Wedbush, Reiterated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $192 on, Nov 8th, 2023.
Andreas has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $113 on, Wednesday, September 6th, 2023
These are the ratings of the 2 analyists that currently disagree with Andreas
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Friday, September 15th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $134 on, Wednesday, September 6th, 2023
Contributing Sources